PT  - JOURNAL ARTICLE
AU  - Sergio Dellepiane
AU  - Akhil Vaid
AU  - Suraj K Jaladanki
AU  - Ishan Paranjpe
AU  - Steven Coca
AU  - Zahi A Fayad
AU  - Alexander W Charney
AU  - Erwin P Bottinger
AU  - John Cijiang He
AU  - Benjamin S Glicksberg
AU  - Lili Chan
AU  - Girish Nadkarni
TI  - Temporal Trends in COVID-19 associated AKI from March to December 2020 in New York City
AID  - 10.1101/2021.01.18.21249414
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.18.21249414
4099  - http://medrxiv.org/content/early/2021/01/20/2021.01.18.21249414.short
4100  - http://medrxiv.org/content/early/2021/01/20/2021.01.18.21249414.full
AB  - Acute Kidney Injury (AKI) is among the most common complications of Coronavirus Disease 2019 (COVID-19). Throughout 2020 pandemic, the clinical approach to COVID-19 has progressively improved, but it is unknown how these changes have affected AKI incidence and severity. In this retrospective analysis, we report the trend over time of COVID-19 associated AKI and need of renal replacement therapy in a large health system in New York City, the first COVID-19 epicenter in United States.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No single patient data have been reported, this is an observational study based on collective data report. The Mount Sinai Institutional Review Board approved this research under a broad regulatory protocol allowing for analysis of patient-level data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request to the authors